Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in this Section 6.6.4, alone or together, reduce the royalties payable by Celgene for a Binder Program Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts otherwise payable by Celgene for such Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth above in this Section 6.6.4(f), to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully deducted, in all cases subject to the limitation set forth above in this Section 6.6.4(f).
Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in Sections 7.2(b), (c) and (d), alone or together, reduce the royalties payable by OV for a given Calendar Quarter pursuant to Section 7.2(a) to less than [***] of the amounts payable by OV for a given Calendar Quarter pursuant to Section 7.2(a). OV may carry over and apply any such royalty reductions which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter, to any subsequent Calendar Quarter(s), and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter.
Cumulative Effect of Royalty Reductions. On a country-by-country basis, in no event will the royalty reductions for Products that Modulate a given Target permitted under Section 11.7.2(a) (Lack of Valid Claims), Section 11.7.2(b) (Loss of Market Exclusivity), or Section 11.7.2(c)(i) (Third Party Licenses), alone or together, reduce the Royalties due to HMI for Products that Modulate such Target pursuant to Section 11.7.1 (Royalty Rates) in a country in a given Calendar Quarter to less than the applicable royalty floor set forth in Table 11.7.1 in such country in such Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. Confidential Treatment Requested by Homology Medicines, Inc. Calendar Quarter (the “Royalty Floor”). [***] Notwithstanding the Royalty Floor or any other limitations set forth in this Section 11.7.3 (Cumulative Effect of Royalty Reductions) and without limiting HMI’s obligations hereunder, if a Third Party threatens to either terminate or diminish the scope or exclusivity of the licenses granted to NVS under any HMI Licensed Technology under a Third Party License to which HMI or its Affiliates is a party, then [***]
Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in Section 5.3, alone or together, reduce the royalties payable by Celgene for a given Calendar Quarter to less than [***] of the amounts payable by Celgene for a given Calendar Quarter pursuant to Exhibits C-1 and C-2. Subject to the previous sentence, Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter, to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter.
Cumulative Effect of Royalty Reductions. On a Licensed Product-by-Licensed Product and country-by-country basis, in no event will the royalty reductions for such Licensed Product permitted under subsections (a) to (c) of this Section 8.6.3, alone or together, reduce the Royalty payments due to Precision with respect to such Licensed Product pursuant to Section 8.6.2 in a country in a given Calendar Quarter by more than [***] of the applicable Royalty payments that would otherwise be owed on the Net Sales of such Licensed Product in such country.
Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in Section 5.4.2 reduce the effective royalty rate payable by Celgene, its Affiliates or Sublicensees with respect to License Net Sales (a) arising from the [***], to less than [***] and (b) arising from [***], to less than [***] (the “Floor Royalty”). For clarity, if [***], and if [***].
Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in Sections 6.6.1 and 6.6.2 and 6.6.3, alone or together, reduce the royalties payable by Celgene for a given Calendar Quarter pursuant to this Section 6.6 to less than [***] for a given Calendar Quarter pursuant to Paragraph 4(a) of Exhibit C-1, C-2 or C-3, as applicable. For clarity, any [***]. Celgene may [***].
Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in this Article 8, alone or together, reduce the royalties payable by HanX for a Product in a country in any given calendar quarter to less than the greater of (a) fifty percent (50%) of the royalty amounts set forth in Section 8.4.1 for such Product in such country in such calendar quarter and (b) [**]of Net Sales in such country; provided that clause (b) shall be applicable to a Product only if and for so long as Onconova is obligated to pay royalty on the Net Sales of such Product to a Third Party under an agreement with such Third Party. HanX may carry over and apply any such royalty reductions, which are incurred or accrued in a calendar quarter and are not deducted in such calendar quarter due to the limitation set forth above in this Section 8.4.3, to any subsequent calendar quarter(s) and shall continue applying such reduction on a calendar quarter basis thereafter until fully deducted, in all cases subject to the limitation set forth above in this Section 8.4.3.
Cumulative Effect of Royalty Reductions. On a [***] basis, in no event will the royalty reductions for a Licensed Product permitted under Section [***] in relation to Improved Licensed Products, PM8003 Licensed Products and/or Preclinical Multispecific Licensed Products reduce the Royalties due to Biotheus for such Licensed Product pursuant to Section 8.5(a) (Royalty Rates for Licensed Products) in a country in a given [***] in the aggregate by [***] of the amount otherwise payable. In the event that BioNTech would, but for the restriction set forth in this Section 8.5(c) (Cumulative Effect of Royalty Reductions), have the right to reduce the Royalties due to Biotheus for a Licensed Product pursuant to Section 8.5(a) (Royalty Rates for Licensed Products) in a country in a [***] under Section 8.5(a) (Royalty Rates for Licensed Products) to [***] then any such unused reduction may be carried forward and used as a credit in one or more future [***] for such Licensed Product in the same country, and such unused reduction shall be carried forward until such time as such unused credit has been exhausted [***].
Cumulative Effect of Royalty Reductions. Subject to Section 6.5.5, in no event shall the royalty reductions described in Sections 6.5.1 and 6.5.2, alone or together, reduce the royalties payable by Celgene pursuant to this Section 6.5 to less than [***] pursuant to Section 6.4.1 or Section 6.4.2, as applicable. Celgene may [***].
